178 related articles for article (PubMed ID: 37870681)
1. Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling.
Hao Y; Chen P; Guo S; Li M; Jin X; Zhang M; Deng W; Li P; Lei W; Liang A; Qian W
Front Med; 2024 Feb; 18(1):128-146. PubMed ID: 37870681
[TBL] [Abstract][Full Text] [Related]
2. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
[TBL] [Abstract][Full Text] [Related]
3. A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma.
Chen X; Li X; Liu Y; Zhang Z; Zhang X; Huang J; Li H; Li F; Zhang L; Li L; Wu X; Ma W; Sun Z; Yu H; Zhou Z; Feng X; Cui K; Li Z; Zhang H; Zeng Y; Wan X; Chen YH; Zhang M; Zhang Y
Immunotherapy; 2020 Jul; 12(10):681-696. PubMed ID: 32580597
[No Abstract] [Full Text] [Related]
4. CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD.
Imura Y; Ando M; Kondo T; Ito M; Yoshimura A
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32525846
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
6. The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice.
Zhao K; Ren C; Tang D; Zhao L; Chen X; Wang Y; Xu K
Front Immunol; 2023; 14():1101769. PubMed ID: 36761733
[TBL] [Abstract][Full Text] [Related]
7. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Schubert ML; Hückelhoven-Krauss A; Xia R; Ge J; Kleist C; Eckstein V; Sellner L; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
Front Immunol; 2021; 12():670088. PubMed ID: 34122428
[TBL] [Abstract][Full Text] [Related]
8. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
10. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
11. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo.
Chen Z; You L; Wang L; Huang X; Liu H; Wei JY; Zhu L; Qian W
J Exp Clin Cancer Res; 2018 Aug; 37(1):190. PubMed ID: 30103789
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of local reactions and efficacy of CD19 chimeric antigen receptor-modified T cells therapy in recurrent/refractory B-cell lymphoma with >7.5 cm lesions].
Li Q; Deng HB; Liu MJ; Lyu CC; Zhu HB; Wang J; Jiang YL; Pu YD; Jiang YY; Li W; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):570-576. PubMed ID: 34455744
[No Abstract] [Full Text] [Related]
13. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
Tsukahara T; Ohmine K; Yamamoto C; Uchibori R; Ido H; Teruya T; Urabe M; Mizukami H; Kume A; Nakamura M; Mineno J; Takesako K; Riviere I; Sadelain M; Brentjens R; Ozawa K
Biochem Biophys Res Commun; 2013 Aug; 438(1):84-9. PubMed ID: 23872144
[TBL] [Abstract][Full Text] [Related]
14. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Chong EA; Alanio C; Svoboda J; Nasta SD; Landsburg DJ; Lacey SF; Ruella M; Bhattacharyya S; Wherry EJ; Schuster SJ
Blood; 2022 Feb; 139(7):1026-1038. PubMed ID: 34496014
[TBL] [Abstract][Full Text] [Related]
17. Point mutation in
Zhang Z; Chen X; Tian Y; Li F; Zhao X; Liu J; Yao C; Zhang Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33023981
[TBL] [Abstract][Full Text] [Related]
18. [Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells].
Xiao X; Yuan T; Meng JX; Jiang YY; Cao YQ; Li Q; Sun R; Zhao MF
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(8):593-598. PubMed ID: 32164113
[No Abstract] [Full Text] [Related]
19. Impact of
Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
[TBL] [Abstract][Full Text] [Related]
20. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]